pubmed-article:14676987 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:14676987 | lifeskim:mentions | umls-concept:C0011684 | lld:lifeskim |
pubmed-article:14676987 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
pubmed-article:14676987 | lifeskim:mentions | umls-concept:C0026447 | lld:lifeskim |
pubmed-article:14676987 | lifeskim:mentions | umls-concept:C0034493 | lld:lifeskim |
pubmed-article:14676987 | lifeskim:mentions | umls-concept:C1280551 | lld:lifeskim |
pubmed-article:14676987 | lifeskim:mentions | umls-concept:C0025914 | lld:lifeskim |
pubmed-article:14676987 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
pubmed-article:14676987 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
pubmed-article:14676987 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
pubmed-article:14676987 | lifeskim:mentions | umls-concept:C0227525 | lld:lifeskim |
pubmed-article:14676987 | lifeskim:mentions | umls-concept:C0025519 | lld:lifeskim |
pubmed-article:14676987 | lifeskim:mentions | umls-concept:C0656510 | lld:lifeskim |
pubmed-article:14676987 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:14676987 | pubmed:dateCreated | 2004-2-10 | lld:pubmed |
pubmed-article:14676987 | pubmed:abstractText | Several cases of death associated with 4-methylthioamphetamine (4-MTA) have raised public concern about the abuse of this designer drug that is usually sold as "Ecstasy" or "Flatliners". Since only very little is known about the metabolism of 4-MTA in humans we performed an in vitro study incubating racemic 4-MTA with primary hepatocytes isolated from three male human donors. Additionally, hepatocytes from male monkey (Cynomolgus), dog (Beagle), rabbit (Chinchilla), rat (Sprague-Dawley), and mouse (CD1) were examined for the metabolism of racemic 4-MTA. We observed that 4-MTA was not extensively metabolised by hepatocytes from all species examined. The main metabolite was identified as 4-methylthiobenzoic acid which, for the first time has been described as a human metabolite. In addition to metabolism we also examined 4-MTA-induced toxicity as evidenced by the ATP cellular content. Interestingly, one of the three human donors showed a dramatically increased sensitivity to the reduction in ATP content induced by 4-MTA. Comparing the species examined, the most extensive formation of 4-methylthiobenzoic acid was observed in the rabbit hepatocytes followed by human, monkey, dog and mouse hepatocytes, whereas no formation of 4-methylthiobenzoic acid was seen in the rat hepatocytes. Toxicity data suggest that rabbit hepatocytes are more resistant to 4-MTA than the other species, which may be due to the more extensive metabolism. In conclusion, we have shown that 4-methylthiobenzoic acid is the main metabolite formed from 4-MTA by human hepatocytes and also by the hepatocytes of the other tested species except the rat. Toxicity data suggest only moderate interspecies differences. | lld:pubmed |
pubmed-article:14676987 | pubmed:language | eng | lld:pubmed |
pubmed-article:14676987 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14676987 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:14676987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14676987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14676987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14676987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14676987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14676987 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:14676987 | pubmed:month | Feb | lld:pubmed |
pubmed-article:14676987 | pubmed:issn | 0028-1298 | lld:pubmed |
pubmed-article:14676987 | pubmed:author | pubmed-author:de BoerDouweD | lld:pubmed |
pubmed-article:14676987 | pubmed:author | pubmed-author:OeschFranzF | lld:pubmed |
pubmed-article:14676987 | pubmed:author | pubmed-author:HengstlerJan... | lld:pubmed |
pubmed-article:14676987 | pubmed:author | pubmed-author:CarvalhoFélix... | lld:pubmed |
pubmed-article:14676987 | pubmed:author | pubmed-author:RemiãoFernand... | lld:pubmed |
pubmed-article:14676987 | pubmed:author | pubmed-author:de Lourdes... | lld:pubmed |
pubmed-article:14676987 | pubmed:author | pubmed-author:CarmoHelenaH | lld:pubmed |
pubmed-article:14676987 | pubmed:author | pubmed-author:dos... | lld:pubmed |
pubmed-article:14676987 | pubmed:author | pubmed-author:FernandesEdua... | lld:pubmed |
pubmed-article:14676987 | pubmed:author | pubmed-author:RingelMichael... | lld:pubmed |
pubmed-article:14676987 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:14676987 | pubmed:volume | 369 | lld:pubmed |
pubmed-article:14676987 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:14676987 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:14676987 | pubmed:pagination | 198-205 | lld:pubmed |
pubmed-article:14676987 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:14676987 | pubmed:meshHeading | pubmed-meshheading:14676987... | lld:pubmed |
pubmed-article:14676987 | pubmed:meshHeading | pubmed-meshheading:14676987... | lld:pubmed |
pubmed-article:14676987 | pubmed:meshHeading | pubmed-meshheading:14676987... | lld:pubmed |
pubmed-article:14676987 | pubmed:meshHeading | pubmed-meshheading:14676987... | lld:pubmed |
pubmed-article:14676987 | pubmed:meshHeading | pubmed-meshheading:14676987... | lld:pubmed |
pubmed-article:14676987 | pubmed:meshHeading | pubmed-meshheading:14676987... | lld:pubmed |
pubmed-article:14676987 | pubmed:meshHeading | pubmed-meshheading:14676987... | lld:pubmed |
pubmed-article:14676987 | pubmed:meshHeading | pubmed-meshheading:14676987... | lld:pubmed |
pubmed-article:14676987 | pubmed:meshHeading | pubmed-meshheading:14676987... | lld:pubmed |
pubmed-article:14676987 | pubmed:meshHeading | pubmed-meshheading:14676987... | lld:pubmed |
pubmed-article:14676987 | pubmed:meshHeading | pubmed-meshheading:14676987... | lld:pubmed |
pubmed-article:14676987 | pubmed:meshHeading | pubmed-meshheading:14676987... | lld:pubmed |
pubmed-article:14676987 | pubmed:meshHeading | pubmed-meshheading:14676987... | lld:pubmed |
pubmed-article:14676987 | pubmed:meshHeading | pubmed-meshheading:14676987... | lld:pubmed |
pubmed-article:14676987 | pubmed:meshHeading | pubmed-meshheading:14676987... | lld:pubmed |
pubmed-article:14676987 | pubmed:meshHeading | pubmed-meshheading:14676987... | lld:pubmed |
pubmed-article:14676987 | pubmed:meshHeading | pubmed-meshheading:14676987... | lld:pubmed |
pubmed-article:14676987 | pubmed:year | 2004 | lld:pubmed |
pubmed-article:14676987 | pubmed:articleTitle | Comparative metabolism of the designer drug 4-methylthioamphetamine by hepatocytes from man, monkey, dog, rabbit, rat and mouse. | lld:pubmed |
pubmed-article:14676987 | pubmed:affiliation | REQUIMTE, Toxicology Department, Faculty of Pharmacy, Porto University, Rua Aníbal Cunha 164, 4050-047 Porto, Portugal. helenacarmo@ff.up.pt | lld:pubmed |
pubmed-article:14676987 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:14676987 | pubmed:publicationType | Comparative Study | lld:pubmed |
pubmed-article:14676987 | pubmed:publicationType | In Vitro | lld:pubmed |
pubmed-article:14676987 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |